Tessa Therapeutics, a clinical-stage immunotherapy company focused on autologous and off-the-shelf, allogeneic therapies targeting solid tumours, has collaborated with United States-based Merck (known as MSD outside the US and Canada), through a subsidiary.
It was reported yesterday that the contract has been signed to assess Tessa Therapeutics' armoured human papillomavirus-specific T cell (HPVST) therapy, or TT12, in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 (programmed death receptor-1) therapy, in patients with recurrent or metastatic HPV 16 and 18-positive cervical cancer.
According to the contract, Tessa Therapeutics will conduct a multi-centre Phase 1b/2 trial to assess the safety and efficacy of the combination. The trial is planned for commencement in the United States, Singapore and South Korea. The company's product is an autologous cell therapy product composed of HPVSTs that have been trained to target HPV 16/18 antigens and genetically modified with a decoy TGF-beta receptor to overcome the suppressive tumour microenvironment.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886